<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Agios Pharm — News on 6ix</title>
    <link>https://6ix.com/company/agios-pharm</link>
    <description>Latest news and press releases for Agios Pharm on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 29 Apr 2026 10:30:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/agios-pharm" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683543db78dffbe2df0e1e4c.webp</url>
      <title>Agios Pharm</title>
      <link>https://6ix.com/company/agios-pharm</link>
    </image>
    <item>
      <title>Agios Reports First Quarter 2026 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/agios-pharm/news/agios-reports-first-quarter-2026-financial-results-and-provides-business-update</link>
      <guid isPermaLink="true">https://6ix.com/company/agios-pharm/news/agios-reports-first-quarter-2026-financial-results-and-provides-business-update</guid>
      <pubDate>Wed, 29 Apr 2026 10:30:00 GMT</pubDate>
      <description>Mitapivat (PYRUKYND® and AQVESME™) generated worldwide net revenues of $20.7 million in the first quarter of 2026, compared to $8.7 million in the first quarter of 2025Strong initial U.S. commercial launch of AQVESME in thalassemia, with 242 prescriptions written as of March 31, 2026Company plans to submit mitapivat sNDA for sickle cell disease in the second quarter of 2026Pipeline advancing to multiple value-driving inflection points in 2026, including two Phase 2 readouts for next-generation P</description>
    </item>
    <item>
      <title>Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET</title>
      <link>https://6ix.com/company/agios-pharm/news/agios-to-host-first-quarter-2026-financial-results-conference-call-and-webcast-on-april-29-at-800-am-et</link>
      <guid isPermaLink="true">https://6ix.com/company/agios-pharm/news/agios-to-host-first-quarter-2026-financial-results-conference-call-and-webcast-on-april-29-at-800-am-et</guid>
      <pubDate>Mon, 06 Apr 2026 11:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Wednesday, April 29, 2026, at 8:00 a.m. ET to report its first quarter 2026 financial results and business highlights. The live webcast will be accessible on the Investors section of the company’s website (</description>
    </item>
    <item>
      <title>Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA</title>
      <link>https://6ix.com/company/agios-pharm/news/agios-advances-mitapivat-toward-potential-us-accelerated-approval-in-sickle-cell-disease-following-pre-snda-meeting-with-fda</link>
      <guid isPermaLink="true">https://6ix.com/company/agios-pharm/news/agios-advances-mitapivat-toward-potential-us-accelerated-approval-in-sickle-cell-disease-following-pre-snda-meeting-with-fda</guid>
      <pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
      <description>Company has already submitted proposed confirmatory trial for FDA review, as required under accelerated approval pathway Company plans to submit mitapivat</description>
    </item>
    <item>
      <title>Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates</title>
      <link>https://6ix.com/company/agios-pharm/news/agios-pyrukyndr-mitapivat-approved-for-adults-with-thalassemia-in-the-united-arab-emirates</link>
      <guid isPermaLink="true">https://6ix.com/company/agios-pharm/news/agios-pyrukyndr-mitapivat-approved-for-adults-with-thalassemia-in-the-united-arab-emirates</guid>
      <pubDate>Mon, 02 Mar 2026 05:00:00 GMT</pubDate>
      <description>PYRUKYND is the only medicine approved in the UAE for adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia NewBridge</description>
    </item>
    <item>
      <title>Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/agios-pharm/news/agios-reports-fourth-quarter-full-113000027</link>
      <guid isPermaLink="true">https://6ix.com/company/agios-pharm/news/agios-reports-fourth-quarter-full-113000027</guid>
      <pubDate>Thu, 12 Feb 2026 11:30:00 GMT</pubDate>
      <description>PYRUKYND® (mitapivat) worldwide net revenues of $20.0 million in fourth quarter and $54.0 million for full yearAQVESME™ (mitapivat) for thalassemia now available in U.S. following FDA approvalCompany will have pre-sNDA meeting with FDA for mitapivat in sickle cell disease in first quarter of 2026Phase 2 tebapivat trial in sickle cell disease fully enrolled; topline results expected in second half of 2026$1.2 billion dollars in cash, cash equivalents, and marketable securities as of December 31,</description>
    </item>
    <item>
      <title>Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET</title>
      <link>https://6ix.com/company/agios-pharm/news/agios-host-fourth-quarter-and-full-year-2025-financial-results-conference-call-and</link>
      <guid isPermaLink="true">https://6ix.com/company/agios-pharm/news/agios-host-fourth-quarter-and-full-year-2025-financial-results-conference-call-and</guid>
      <pubDate>Mon, 26 Jan 2026 05:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on</description>
    </item>
    <item>
      <title>Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth</title>
      <link>https://6ix.com/company/agios-pharm/news/agios-outlines-2026-strategic-priorities-and-key-milestones-accelerate-rare-disease</link>
      <guid isPermaLink="true">https://6ix.com/company/agios-pharm/news/agios-outlines-2026-strategic-priorities-and-key-milestones-accelerate-rare-disease</guid>
      <pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
      <description>AQVESME™ (mitapivat) U.S. commercial launch in thalassemia underway following December 2025 FDA approvalPre-sNDA meeting with FDA for mitapivat in sickle cell</description>
    </item>
    <item>
      <title>Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026</title>
      <link>https://6ix.com/company/agios-pharm/news/agios-present-44th-annual-jp-morgan-healthcare-conference-january-14-2026-2026-01-05</link>
      <guid isPermaLink="true">https://6ix.com/company/agios-pharm/news/agios-present-44th-annual-jp-morgan-healthcare-conference-january-14-2026-2026-01-05</guid>
      <pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on</description>
    </item>
    <item>
      <title>U.S. FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia</title>
      <link>https://6ix.com/company/agios-pharm/news/us-fda-approves-agios-aqvesmetm-mitapivat-treatment-anemia-adults-alpha-or-beta</link>
      <guid isPermaLink="true">https://6ix.com/company/agios-pharm/news/us-fda-approves-agios-aqvesmetm-mitapivat-treatment-anemia-adults-alpha-or-beta</guid>
      <pubDate>Tue, 23 Dec 2025 05:00:00 GMT</pubDate>
      <description>AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemiaMarketed under</description>
    </item>
    <item>
      <title>Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia</title>
      <link>https://6ix.com/company/agios-pharm/news/agios-provides-update-us-snda-mitapivat-thalassemia-2025-12-08</link>
      <guid isPermaLink="true">https://6ix.com/company/agios-pharm/news/agios-provides-update-us-snda-mitapivat-thalassemia-2025-12-08</guid>
      <pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on</description>
    </item>
    <item>
      <title>Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease</title>
      <link>https://6ix.com/company/agios-pharm/news/agios-announces-topline-results-rise-phase-3-trial-mitapivat-sickle-cell-disease-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/agios-pharm/news/agios-announces-topline-results-rise-phase-3-trial-mitapivat-sickle-cell-disease-2025</guid>
      <pubDate>Wed, 19 Nov 2025 05:00:00 GMT</pubDate>
      <description>Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentration and indirect bilirubin Trial</description>
    </item>
    <item>
      <title>Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition</title>
      <link>https://6ix.com/company/agios-pharm/news/agios-present-new-mitapivat-data-rare-blood-disorders-67th-ash-annual-meeting-and</link>
      <guid isPermaLink="true">https://6ix.com/company/agios-pharm/news/agios-present-new-mitapivat-data-rare-blood-disorders-67th-ash-annual-meeting-and</guid>
      <pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on</description>
    </item>
    <item>
      <title>Agios Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/agios-pharm/news/agios-reports-third-quarter-2025-financial-results-and-provides-business-update-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/agios-pharm/news/agios-reports-third-quarter-2025-financial-results-and-provides-business-update-2025</guid>
      <pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
      <description>$12.9 million in third quarter PYRUKYND® (mitapivat) net revenuesPDUFA goal date for PYRUKYND U.S. sNDA in thalassemia set for December 7, 2025CHMP adopted</description>
    </item>
    <item>
      <title>Agios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia</title>
      <link>https://6ix.com/company/agios-pharm/news/agios-pyrukyndr-mitapivat-receives-positive-chmp-opinion-adults-thalassemia-2025-10</link>
      <guid isPermaLink="true">https://6ix.com/company/agios-pharm/news/agios-pyrukyndr-mitapivat-receives-positive-chmp-opinion-adults-thalassemia-2025-10</guid>
      <pubDate>Fri, 17 Oct 2025 04:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on</description>
    </item>
    <item>
      <title>Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET</title>
      <link>https://6ix.com/company/agios-pharm/news/agios-host-third-quarter-2025-financial-results-conference-call-and-webcast-october</link>
      <guid isPermaLink="true">https://6ix.com/company/agios-pharm/news/agios-host-third-quarter-2025-financial-results-conference-call-and-webcast-october</guid>
      <pubDate>Thu, 16 Oct 2025 04:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on</description>
    </item>
    <item>
      <title>Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia</title>
      <link>https://6ix.com/company/agios-pharm/news/agios-provides-update-us-pdufa-goal-date-pyrukyndr-mitapivat-thalassemia-2025-09-04</link>
      <guid isPermaLink="true">https://6ix.com/company/agios-pharm/news/agios-provides-update-us-pdufa-goal-date-pyrukyndr-mitapivat-thalassemia-2025-09-04</guid>
      <pubDate>Thu, 04 Sep 2025 04:00:00 GMT</pubDate>
      <description>PDUFA goal date extended by three months from September 7, 2025, to December 7, 2025 CAMBRIDGE, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Agios</description>
    </item>
    <item>
      <title>Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia</title>
      <link>https://6ix.com/company/agios-pharm/news/agios-pyrukyndr-mitapivat-approved-adults-thalassemia-saudi-arabia-2025-08-04</link>
      <guid isPermaLink="true">https://6ix.com/company/agios-pharm/news/agios-pyrukyndr-mitapivat-approved-adults-thalassemia-saudi-arabia-2025-08-04</guid>
      <pubDate>Mon, 04 Aug 2025 04:00:00 GMT</pubDate>
      <description>First regulatory approval for PYRUKYND in thalassemia, evaluated under SFDA’s Breakthrough Medicines Program Agios partnered with NewBridge Pharmaceuticals, a</description>
    </item>
    <item>
      <title>Agios Reports Second Quarter 2025 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/agios-pharm/news/agios-reports-second-quarter-2025-financial-results-and-provides-business-update-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/agios-pharm/news/agios-reports-second-quarter-2025-financial-results-and-provides-business-update-2025</guid>
      <pubDate>Thu, 31 Jul 2025 04:00:00 GMT</pubDate>
      <description>$12.5 million in second quarter PYRUKYND® (mitapivat) net revenues; ended second quarter with $1.3 billion dollars in cash, cash equivalents and marketable</description>
    </item>
    <item>
      <title>Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET</title>
      <link>https://6ix.com/company/agios-pharm/news/agios-host-webcast-conference-call-second-quarter-financial-results-july-31-2025-8</link>
      <guid isPermaLink="true">https://6ix.com/company/agios-pharm/news/agios-host-webcast-conference-call-second-quarter-financial-results-july-31-2025-8</guid>
      <pubDate>Mon, 14 Jul 2025 04:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK)</description>
    </item>
    <item>
      <title>Agios Appoints Dr. Jay Backstrom to Board of Directors</title>
      <link>https://6ix.com/company/agios-pharm/news/agios-appoints-dr-jay-backstrom-board-directors-2025-07-08</link>
      <guid isPermaLink="true">https://6ix.com/company/agios-pharm/news/agios-appoints-dr-jay-backstrom-board-directors-2025-07-08</guid>
      <pubDate>Tue, 08 Jul 2025 04:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK)</description>
    </item>
  </channel>
</rss>